
It’s only four months since Gilead completed its buy-out of Kite Pharma for $11.9 billion, but it’s already moving quickly …

Since Sanofi released further data from a six-year study which showed that the risk of a severe dengue reaction is …

Sage Therapeutics’ stock rocketed after it announced that Phase 2 results for its treatment for major depressive disorder (MDD) were …

We’ve finally reached the starter’s block when it comes to precision medicine approaches to prostate cancer, but Dr Matthew Hobbs, …

A Phase 3 trial looking at the use of Kisqali (ribociclib) to treat premenopausal or perimenopausal women with hormone-receptor positive, …

Disulfiram has been known as an anti-drinking compound for nearly seven decades. Initially, the compound was used in the vulcanisation …

Bioethics international, a non-profit organisation, has published its second annual index ranking pharma companies by the transparency of data from …

Novartis and GSK have been taken to court by the Australian Competition and Consumer Commission (ACCC) over allegations of falsely …

In the latest boost to the UK’s life sciences strategy, GSK has committed £40 million to its work identifying new …

Veeva took the opportunity at its European Commercial & Medical Summit to reveal the latest upgrade to its Veeva CRM …

Building on their previous research emerging from Professor Roy Taylor’s work at Newcastle University, a study has found that 45.6% …

Psoriasis is a big pharmaceutical market, it’s the most common autoimmune disease in the US and as many as 7.5 …

AbbVie revealed that its IL-23 inhibitor, risankizumab, had successfully met all of its endpoints in a Phase 3 trials into …

We are proud to be partnering with the ProcureCon Pharma 2018, the only event in Europe for senior pharma procurement …

Derek Wallace, Global Dengue Program Head at Takeda Vaccine Business Unit, discusses the recent Phase 2 results showing its vaccine …